Common use of IMMEDIATE ATTENTION REQUIRED Clause in Contracts

IMMEDIATE ATTENTION REQUIRED. This Questionnaire is being furnished to all persons or entities (the “Investors”) electing to purchase shares of Common Stock (“Common Stock”) of Selecta Biosciences, Inc. (the “Company”) pursuant to the Securities Purchase Agreement by and among the Company and the Investors (the “Purchase Agreement”) to which this Questionnaire is an Appendix. This Questionnaire relates to certain information required to be disclosed in the registration statement (the “Registration Statement”) being prepared by the Company for filing with the United States Securities and Exchange Commission (the “SEC”) pursuant to the Registration Rights Agreement entered into by and among the Company and the Investors (the “Registration Rights Agreement”) in connection with the Purchase Agreement. The Company must receive a completed Questionnaire from each Investor in order to include such Investor’s shares of Common Stock in the Registration Statement. The furnishing of accurate and complete responses to the questions posed in this Questionnaire is an extremely important part of the registration process. The inclusion of inaccurate or incomplete disclosures in the Registration Statement can result in potential liabilities, both civil and criminal, to the Company and to the individuals who furnish the information. Accordingly, Investors are advised to consult their own securities law counsel regarding the consequences of being named or not being named as a selling securityholder in the Registration Statement and related prospectus.

IMMEDIATE ATTENTION REQUIRED. This Questionnaire is being furnished to all persons or entities (the “InvestorsPurchasers”) electing to purchase who purchased shares of Common Stock (“Common Stock”) of Selecta Biosciences, Inc. ClearSign Combustion Corporation (the “Company”) pursuant to the Securities Stock Purchase Agreement by and among the Company and the Investors Purchaser (the “Purchase Agreement”) to which this Questionnaire is an Appendix). This Questionnaire relates to certain information required to be disclosed in the registration statement Registration Statement on Form S-3 (the “Registration Statement”) being to be prepared by the Company for filing with the United States Securities and Exchange Commission (the “SEC”) pursuant to the Registration Rights Agreement entered into by and among the Company and the Investors Purchaser (the “Registration Rights Agreement”) in connection with the Purchase Agreement. The Company must receive a completed Questionnaire from each Investor Purchaser in order to include such InvestorPurchaser’s shares of Common Stock in the Registration Statement. The furnishing of accurate and complete responses to the questions posed in this Questionnaire is an extremely important part of the registration process. The inclusion of inaccurate or incomplete disclosures in the Registration Statement can result in potential liabilities, both civil and criminal, to the Company and to the individuals who furnish the information. Accordingly, Investors are Purchaser is advised to consult their its own securities law counsel regarding the consequences of being named or not being named as a selling securityholder in the Registration Statement and related prospectus.

IMMEDIATE ATTENTION REQUIRED. This Questionnaire is being furnished to all persons or entities (the “InvestorsPurchasers”) electing to purchase shares of Common Stock (“Common Stock”) of Selecta BiosciencesArdelyx, Inc. (the “Company”) pursuant to the Securities Purchase Agreement by and among the Company and the Investors Purchasers (the “Purchase Agreement”) to which this Questionnaire is an Appendix. This Questionnaire relates to certain information required to be disclosed in the registration statement (the “Registration Statement”) Statement on Form S-3 being prepared by the Company for filing with the United States Securities and Exchange Commission (the “SEC”) pursuant to the Registration Rights Agreement entered into by and among the Company and the Investors Purchasers (the “Registration Rights Agreement”) in connection with the Purchase Agreement. The Company must receive a completed Questionnaire from each Investor Purchaser in order to include such InvestorPurchaser’s shares of Common Stock in the Registration Statement. The furnishing of accurate and complete responses to the questions posed in this Questionnaire is an extremely important part of the registration process. The inclusion of inaccurate or incomplete disclosures in the Registration Statement can result in potential liabilities, both civil and criminal, to the Company and to the individuals who furnish the information. Accordingly, Investors Purchasers are advised to consult their own securities law counsel regarding the consequences of being named or not being named as a selling securityholder in the Registration Statement and related prospectus.

IMMEDIATE ATTENTION REQUIRED. This Questionnaire is being furnished to all persons or entities (the “Investors”) electing to purchase shares units, consisting of Common Stock one share of common stock (“Common Stock”) and one warrant to purchase 0.5 of Selecta Biosciencesa share of Common Stock of MEI Pharma, Inc. (the “Company”) pursuant to the Securities Purchase Agreement by and among the Company and the Investors (the “Purchase Agreement”) to which this Questionnaire is an Appendix. This Questionnaire relates to certain information required to be disclosed in the registration statement (the “Registration Statement”) being prepared by the Company for filing with the United States Securities and Exchange Commission (the “SEC”) pursuant to the Registration Rights Agreement entered into by and among the Company and the Investors (the “Registration Rights Agreement”) in connection with the Purchase Agreement. The Company must receive a completed Questionnaire from each Investor in order to include such Investor’s shares of Common Stock in the Registration Statement. The furnishing of accurate and complete responses to the questions posed in this Questionnaire is an extremely important part of the registration process. The inclusion of inaccurate or incomplete disclosures in the Registration Statement can result in potential liabilities, both civil and criminal, to the Company and to the individuals who furnish the information. Accordingly, Investors are advised to consult their own securities law counsel regarding the consequences of being named or not being named as a selling securityholder in the Registration Statement and related prospectus.

IMMEDIATE ATTENTION REQUIRED. This Questionnaire is being furnished to all persons or entities (the “InvestorsPurchasers”) electing to purchase shares of Common Stock (“Common Stock”) of Selecta BiosciencesT2 Biosystems, Inc. (the “Company”) pursuant to the Securities Stock Purchase Agreement by and among the Company and the Investors Purchaser (the “Purchase Agreement”) to which this Questionnaire is an Appendix. This Questionnaire relates to certain information required to be disclosed in the registration statement Registration Statement on Form S-3 (the “Registration Statement”) being to be prepared by the Company for filing with the United States Securities and Exchange Commission (the “SEC”) pursuant to the Registration Rights Agreement entered into by and among the Company and the Investors Purchaser (the “Registration Rights Agreement”) in connection with the Purchase Agreement. The Company must receive a completed Questionnaire from each Investor Purchaser in order to include such InvestorPurchaser’s shares of Common Stock in the Registration Statement. The furnishing of accurate and complete responses to the questions posed in this Questionnaire is an extremely important part of the registration process. The inclusion of inaccurate or incomplete disclosures in the Registration Statement can result in potential liabilities, both civil and criminal, to the Company and to the individuals who furnish the information. Accordingly, Investors are Purchaser is advised to consult their its own securities law counsel regarding the consequences of being named or not being named as a selling securityholder in the Registration Statement and related prospectus.

IMMEDIATE ATTENTION REQUIRED. This Questionnaire is being furnished to all persons or entities (the “Investors”"Purchasers") electing to purchase shares of Common Stock (“"Common Stock”") of Selecta Biosciences, Orgenesis Inc. (the “"Company”") pursuant to the Securities Purchase Agreement by and among the Company and the Investors Purchasers (the “"Purchase Agreement”") to which this Questionnaire is an Appendix. This Questionnaire relates to certain information required to be disclosed in the registration statement (the “Registration Statement”) Statement on Form S-3 being prepared by the Company for filing with the United States Securities and Exchange Commission (the “"SEC”") pursuant to the Registration Rights Agreement entered into by and among the Company and the Investors Purchasers (the “"Registration Rights Agreement”") in connection with the Purchase Agreement. The Company must receive a completed Questionnaire from each Investor Purchaser in order to include such Investor’s Purchaser's shares of Common Stock in the Registration Statement. The furnishing of accurate and complete responses to the questions posed in this Questionnaire is an extremely important part of the registration process. The inclusion of inaccurate or incomplete disclosures in the Registration Statement can result in potential liabilities, both civil and criminal, to the Company and to the individuals who furnish the information. Accordingly, Investors Purchasers are advised to consult their own securities law counsel regarding the consequences of being named or not being named as a selling securityholder in the Registration Statement and related prospectus.